| Ytd | 25.82% | |
| 1y | 5.49% |
| Open | 3.42 | Prev Close | 3.41 | Low | 3.42 | High | 3.60 | Mkt Cap | 394.60M |
| Vol | 1.72M | Avg Vol | 1.62M | EPS | -1.41 | P/E | N/A | Forward P/E | -2.91 |
| Beta | 1.47 | Short Ratio | 4.69 | Inst. Own | 81.43% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 05-11 | 50-d Avg | 3.62 | 200-d Avg | 3.59 | 1yr Est | 16.15 |
CATX News
Perspective Therapeutics, Inc. ("Perspective," the "Company," "we," "us,
One new responder observed in the [212Pb]VMT01 3.0 mCi monotherapy cohort for a total of two confirm
The first patient was treated with [212Pb]VMT-α-NET in a fourth cohort of the Company's ongoing
Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.25) per share which beat the a
Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperf
BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maint
Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperf
Perspective Therapeutics, Inc. ("Perspective" or the "Company) (NYSE:CATX), a radiopharm
HC Wainwright & Co. analyst Robert Burns maintains Perspective Therapeutics (AMEX:CATX) with
B. Riley Securities analyst Yuan Zhi maintains Perspective Therapeutics (AMEX:CATX) with a Buy an
UBS analyst David Dai maintains Perspective Therapeutics (AMEX:CATX) with a Buy and raises the pr
Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperf
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radio
RBC Capital analyst Leonid Timashev maintains Perspective Therapeutics (AMEX:CATX) with a Outperf
BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maint
Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.51) per share which missed the
Piper Sandler analyst Biren Amin initiates coverage on Perspective Therapeutics (AMEX:CATX) with
HC Wainwright & Co. analyst Robert Burns maintains Perspective Therapeutics (AMEX:CATX) with
Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperf
BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maint
Continued strong patient recruitment in neuroendocrine tumors for lead program VMT-α-NET sets the st
Updated interim results with an additional ~13 weeks of follow-up since the prior update[212Pb]VMT-α
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radio
Truist Securities analyst Gregory Renza assumes Perspective Therapeutics (AMEX:CATX) with a Buy r
UBS analyst David Dai maintains Perspective Therapeutics (AMEX:CATX) with a Buy and lowers the pr
B. Riley Securities analyst Yuan Zhi maintains Perspective Therapeutics (AMEX:CATX) with a Buy an
Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.35) per share which missed the
Updated interim results with an additional ~19 weeks of follow-up since the prior update[212Pb]VMT-α
BTIG analyst Jeet Mukherjee reiterates Perspective Therapeutics (AMEX:CATX) with a Buy and maint
BTIG analyst Jeet Mukherjee initiates coverage on Perspective Therapeutics (AMEX:CATX) with a Bu
HC Wainwright & Co. analyst Robert Burns reiterates Perspective Therapeutics (AMEX:CATX) with
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radio
HC Wainwright & Co. analyst Robert Burns reiterates Perspective Therapeutics (AMEX:CATX) with
First patient dosed with [212Pb]VMT01 3.0 mCi in combination with nivolumab[212Pb]VMT01 3.0 mCi sing
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radio
Perspective Therapeutics (AMEX:CATX) reported quarterly losses of $(0.30) per share which met the an
Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE:CATX), a radio
B. Riley Securities analyst Yuan Zhi maintains Perspective Therapeutics (AMEX:CATX) with a Buy an
Wedbush analyst David Nierengarten reiterates Perspective Therapeutics (AMEX:CATX) with a Outperf